Eisai Could Have Difficulty Ending Market Deal With Pfizer
This article was originally published in PharmAsia News
Executive SummaryEisai's attempt to extricate itself from a marketing agreement with U.S.-based Pfizer for Eisai's Aricept (donepezil) for treating Alzheimer's disease may not be as easy as it thought. Eisai sought to end the deal after Pfizer announced it would take over another U.S. firm, Wyeth, but Pfizer is resisting the breakup. Eisai contends the merger with Wyeth violates Pfizer's contract with Eisai, so the contract has been nullified. At stake are huge sales commissions Eisai pays to Pfizer to market Eisai's best-selling drug. Eisai says it can do the marketing itself. (Click here for more - a subscription may be required
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.